(Reuters) — Catalent (NYSE:CTLT) Inc reported a 17% fall in quarterly revenue on Tuesday, hurt by persistent production-related challenges at the contract drug manufacturer's major facilities.
The company also said it was delaying its annual report.
Read more on investing.com